Morningstar

FDA Approves Novo Nordisk's Growth Disorder Treatment For New Populations

Provided by Dow Jones

By Katherine Hamilton 




  Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone. 



  Sogroya is now indicated for kids aged 2.5 years and older with disorders affecting their height, including idiopathic short stature, short stature born small for gestational age, or growth failure associated with Noonan Syndrome. 



  It is also indicated for children of the same age group and adults with growth hormone deficiency. 



  Sogroya is a once-weekly injection which comes in 5 mg, 10 mg and 15 mg dosages. 



   Novo Nordisk has been studying Sogroya as a way for people with growth disorders to avoid daily injections. In a study, Sogroya demonstrated non-inferiority compared with daily somatropin and growth hormone dosages. 



  Novo Nordisk also submitted a supplemental application for Sogroya's approval in the U.S. for Turner Syndrome. A decision is expected later this year, the company said. 





  Write to Katherine Hamilton at katherine.hamilton@wsj.com 





  (END) Dow Jones Newswires



  February 27, 2026 16:33 ET (21:33 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Buy Trading at Big Discounts
 
Plus, what recent bond market volatility means for investors. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
This Once-Hot AI Stock Now Looks Deeply Undervalued
 
This chip stock looks cheap at a 30% discount, and its biggest growth years could still be ahead. 
 
 
William Kerwin, CFA 
 
 
 
What 7 Key Market Indicators Are Telling Investors Right Now
 
US equity valuations have retreated from their recent highs, but all 7 major market indicators remain above their long-term averages. 
 
 
Amy C. Arnott, CFA 
 
 
 
Don’t Overlook the Income Side of Fixed Income
 
Amid bond market tumult, elevated yields are contributing to returns and offering investors a nice income stream. 
 
 
Dan Lefkovitz 
 
 
 
This Vanguard Fund Has Proved Its Defensive Chops
 
Vanguard Global Minimum Volatility has a system for smoothing equity market ups and downs. 
 
 
Taylor Smith 
 
 
 
 

			Sponsor Center